Syncromune, Inc., a clinical stage biopharmaceutical company focused on the development of intratumoral immunotherapy announced today that Charles J. Link, M.D., Executive Chairman & Chief Medical Officer of Syncromune will deliver a presentation at the 2022 BIO CEO & Investor Conference.
February 11, 2022
· 4 min read